Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route (Ascending) Package Effective Date Package Discontinuation Date Status
68001-0282-25 68001-0282 Gemcitabine Hydrochloride Gemcitabine Hydrochloride 38.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous May 23, 2016 Aug. 1, 2021 No Longer Used
68001-0282-26 68001-0282 Gemcitabine Hydrochloride Gemcitabine Hydrochloride 38.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous May 23, 2016 Aug. 1, 2021 No Longer Used
68001-0282-27 68001-0282 Gemcitabine Hydrochloride Gemcitabine Hydrochloride 38.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous May 23, 2016 Aug. 1, 2021 No Longer Used
68001-0284-25 68001-0284 Irinotecan Hydrochloride Irinotecan Hydrochloride 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous May 31, 2016 March 1, 2021 In Use
68001-0284-34 68001-0284 Irinotecan Hydrochloride Irinotecan Hydrochloride 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous May 31, 2016 March 1, 2021 In Use
68001-0425-35 68001-0425 Irinotecan Hydrochloride Irinotecan Hydrochloride 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous July 7, 2020 Aug. 11, 2021 No Longer Used
68001-0426-22 68001-0426 Irinotecan Hydrochloride Irinotecan Hydrochloride 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous July 7, 2020 Aug. 11, 2021 No Longer Used
69097-0313-37 69097-0313 Gemcitabine Hydrochloride Gemcitabine Hydrochloride 200.0 mg/5mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous July 25, 2011 In Use
69097-0314-42 69097-0314 Gemcitabine Hydrochloride Gemcitabine Hydrochloride 1.0 g/25mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous July 25, 2011 In Use
69097-0369-32 69097-0369 Docetaxel Anhydrous Docetaxel Anhydrous 20.0 mg/2mL Chemotherapy Antimitotic Agent Taxane Intravenous Aug. 24, 2018 Aug. 26, 2020 No Longer Used
69097-0371-37 69097-0371 Docetaxel Anhydrous Docetaxel Anhydrous 80.0 mg/8mL Chemotherapy Antimitotic Agent Taxane Intravenous Aug. 24, 2018 Aug. 26, 2020 In Use
69097-0805-40 69097-0805 Azacitidine Azacitidine For 100.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous March 26, 2019 In Use
69171-0398-01 69171-0398 Irinotecan Hydrochloride Onivyde 4.3 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Oct. 22, 2015 Sept. 30, 2019 No Longer Used
70860-0216-10 70860-0216 Busulfan Busulfan 6.0 mg/mL Chemotherapy Alkylating Agent Alkylsulfonate Intravenous Feb. 10, 2019 July 31, 2021 No Longer Used
75834-0190-01 75834-0190 Decitabine Decitabine 50.0 mg/20mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Dec. 17, 2020 In Use
72205-0061-01 72205-0061 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Aug. 26, 2020 In Use
71288-0158-96 71288-0158 Busulfan Busulfan 6.0 mg/mL Chemotherapy Alkylating Agent Alkylsulfonate Intravenous Oct. 23, 2020 In Use
71288-0132-90 71288-0132 Melphalan hydrochloride Melphalan hydrochloride Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous May 28, 2021 In Use
71288-0119-20 71288-0119 Decitabine Decitabine 50.0 mg/20mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous July 2, 2021 In Use
72205-0083-01 72205-0083 Fosaprepitant Fosaprepitant 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous May 12, 2020 In Use
00002-8926-01 00002-8926 Olaratumab Lartruvo 10.0 mg/mL Immunotherapy Monoclonal Antibody PDGFR Intravenous Oct. 19, 2016 Nov. 27, 2020 No Longer Used
00003-2327-11 00003-2327 Ipilimumab Yervoy 5.0 mg/mL Immunotherapy Checkpoint Inhibitor CTLA-4 Intravenous March 25, 2011 In Use
00003-2328-22 00003-2328 Ipilimumab Yervoy 5.0 mg/mL Immunotherapy Checkpoint Inhibitor CTLA-4 Intravenous March 25, 2011 In Use
00006-3029-02 00006-3029 Pembrolizumab Keytruda 50.0 mg/2mL Immunotherapy Checkpoint Inhibitor PD-1 Intravenous Sept. 4, 2014 Dec. 21, 2015 In Use
00006-3941-01 00006-3941 Fosaprepitant Dimeglumine Emend 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Nov. 19, 2010 In Use

Found 10,000 results in 3 milliseconds — Export these results